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ABSTRACT
Prostate cancer can be targeted by ligands to the prostate-specific membrane 
antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-
PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant 
prostate cancer (mCRPC).
Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 
10) 177Lu-PSMA-617 at an eight to ten weeks interval. For safety monitoring, each 
treatment was followed by dosimetry with serial quantitative SPECT as well as 
inpatient and outpatient recording of adverse events. Response to RLT was primarily 
determined by baseline to follow-up change in 68Ga-PSMA PET/CT (RECIST1.1), as 
well as change in prostate-specific antigen (PSA), quality of life (QoL, FACT-P scale), 
and pain (Brief Pain Inventory) as secondary endpoints.
Radiation dose delivered to the tumor (6.1 Gy/GBq) was six to twelve-fold 
higher than to critical organs (kidney left/right 0.5/0.6 Gy/GBq each, salivary glands 
1.0 Gy/GBq). Total radiation dose per kidney did not exceed 23 Gy in any patient. 
Three patients had sub-acute and latent grade 3 events, i.e. anemia, leukocytopenia, 
and nausea. No acute events, grade ≥4 events or high grade events for salivary 
gland or kidney function were observed. After two RLT cycles, 4 (27%) patients had 
partial response, 6 (40%) had stable disease, and 5 (33%) had progressive disease 
according to RECIST. Any PSA decline was observed in 12/15 (80%) patients during 
RLT. Significant pain relief was documented in 7/10 (70%) symptomatic patients and 
QoL improved in 9/15 (60%) patients.
177Lu-PSMA-617 therapy proved safe and indicated promising response rates for 
both objective and patient-reported outcomes in our small group of mCRPC patients.
INTRODUCTION
After non-melanoma skin tumors, prostate cancer 
(PCa) is the second most common malignancy in men, and 
ultimately causes more than 250,000 deaths worldwide 
each year [1]. Radionuclide therapy has become an 
effective treatment option for metastatic disease with 
the approval of bone seeking radiopharmaceuticals; 
systemic application of the calcium ion mimetic 223Ra 
improves survival in patients with castration-resistant 
PCa and symptomatic bone metastases [2]. However, 
about one third of patients with metastatic castration-
resistant prostate cancer (mCRPC) present with lymph 
node or visceral metastases, which are un-responsive 
to bone-seeking agents [3]. Radiolabeled ligands to 
the prostate-specific membrane antigen (PSMA) have 
recently been developed to image and target systemic 
disease. PSMA is over-expressed in PCa, and this over 
expression increases further in cases of de-differentiated, 
metastatic or hormone-refractory disease [4]. The 177Lu 
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labeled small molecule ligand DKFZ-PSMA-617 (177Lu-
PSMA-617) binds with high affinity to PSMA in vitro 
and in vivo [5-6]. The potential of 177Lu-PSMA-617 for 
radioligand therapy (RLT) has been explored in several 
preclinical and clinical studies, among which our previous 
report on human dosimetry demonstrated favorable body 
distribution and high tumor-to-organ uptake ratios [6]. 
Based on our dosimetry calculations, we identified kidney 
as activity-limiting organ and recommended 6.0 GBq as an 
appropriate activity for the initial 177Lu-PSMA-617 RLT 
cycle [6], giving high tumor dosing without excessive 
irradiation of vulnerable healthy organs. Following upon 
this result, we now aim to provide data on clinical safety 
and efficacy of 177Lu-PSMA-617 RLT in an expanded 
patient cohort after a total of 30 177Lu-PSMA-617 RLT 
cycles. Efficacy was based both on objective endpoints 
and patient-reported metrics, including pain intensity 
and quality of life (QoL) scores. To complete dose 
safety evaluation, we further aimed to perform accurate 
dosimetry of salivary glands, the organ with highest 
absorbed radiation dose.
RESULTS
Characteristics of the study cohort
Baseline clinical and demographic characteristics 
are given in Table 1. All patients completed two cycles 
of RLT. Five patients were unfit for chemotherapy prior 
to RLT. 14 of 15 (93%) patients underwent Abiraterone 
Table 1: Baseline characteristics of the patients.
Characteristic (n = 15) Median (range) or total number (%)




















Lactate dehydrogenase (U/L) 287 (167 - 1220)
Hemoglobin (g/dL) 12.3 (8.3 - 15.5)
Total alkaline phosphatase (U/L) 147 (49 - 420)
PSA (μg/L) 388 (3.2 - 10661)









Prior 223Ra 5 (33%)
Prior EBRT 9 (60%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group Performance Status; EBRT, External Beam Radiation Therapy.
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or Enzalutamide therapy before 177Lu-PSMA-617 RLT. 
One patient did not tolerate second or third line hormonal 
therapy. Patients had undergone a median of 3 (range, 
1 to 5) courses of hormonal therapy prior to admission. 
Patients with ongoing hormonal therapy at the start of RLT 
continued their therapy until at least the final follow-up 
in the present study. None of the patients discontinued 
gonadotropin-releasing hormone analogs within three 
months before RLT.
Dosimetry
Mean±SD radiation dose by organ calculated 
from serial quantitative SPECT and blood activity 
concentrations is given in Table 2. The highest organ 
radiation dose was observed for salivary glands (1.0±0.6 
Gy/GBq) and kidneys (right/left 0.6±0.2/0.5±0.3 Gy/
GBq). The mean radiation dose to tumor lesions was 
6.1±4.9 Gy/GBq resulting in a mean tumor-to-kidney 
dose ratio of 11.1 and mean tumor-to-salivary-gland ratio 
of 6.1. Liver, spleen and bone marrow all received doses ≤ 
0.1 Gy/GBq. Maximum cumulative kidney dose (10.3 Gy) 
and salivary gland dose (16.5 Gy) were below the dose 
range reported as critical (23 Gy for kidney [7]; 26-50 Gy 
[8-9] for salivary glands).
Safety
No acute or grade ≥4 adverse events were observed. 
Sub-acute and latent adverse events occurring in at least 
one patient are listed in Table 3. Grade 1 and 2 adverse 
events occurred almost equally often in patients with 
3.7 versus 6.0 GBq RLT (3.4 events/patient versus 4.2 
events/patient). During inpatient stay, one instance of 
grade 3 anemia, and during follow-up one case of grade 
3 leukocytopenia were noted in patients with 6.0 GBq 
RLT; both conditions had improved at final follow-up 
without requiring transfusion or bone marrow stimulation. 
No event for neutropenia was recorded. At intermediate 
follow-up, grade 3 nausea was noted in one patient after 
the second cycle of 3.7 GBq RLT, which responded well 
to antiemetic medication. Mild or transient xerostomia 
was reported both for patients with salivary gland dose 
above (n = 4) versus below (n = 3) the median. One patient 
Figure 1: Response after two cycles of 6.0 GBq 177Lu-PSMA-617 RLT. Axial 68Ga-PSMA PET B. and D. and CT A. and C. 
images of the abdomen before (A and B) and after (C and D) two RLT cycles. Lymph node metastases demonstrate a >30% baseline to 
follow-up decrease in short axis diameter (A and C, arrows) and SUVmax (B, arrows). Compression of the inferior vena cava by lymph node 
metastases at baseline (A, double arrow) was resolved at follow-up (C, double arrow).
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presented with new onset of epigastric pain and markedly 
elevated gamma-glutamyl transferase at final follow-up. 
PET/CT demonstrated progression of liver metastases with 
infiltration of hepatic veins and intrahepatic cholestasis. 
The patient died six weeks later from acute liver failure 
associated with progressive tumor infiltration. In total, 
four patients died from PCa-related events during the 
observation period, at 24, 28, 36 and 42 weeks after start 
of RLT.
Efficacy
Response after one cycle and two cycles of RLT 
is given separately in Table 4. Ten (67%) patients had 
measurable target lesions by RECIST1.1. According to 
RECIST1.1, 4 (27%) patients had PR, 6 (40%) patients 
had SD, and 5 (33%) patients had PD. Images from two 
patients with partial response by CT criteria are shown in 
Figures 1 and 2. Each 7 (47%) patients had biochemical 
partial response by PSA level after the first and second 
cycle, respectively. Bone pain was completely resolved 
in 3 (20%) and responded well in 4 (27%) symptomatic 
patients after two RLT cycles. One and 3 (20%) patients 
had increase in pain intensity after the first and second 
RLT cycle, respectively. QoL was improved in 8 (53%) 
patients and 3 (20%) patients had a 30% or more increase 
in QoL score after the second cycle.
Best response observed for PSA, pain score and 
final response by QoL score are shown for each patient 
in Figure 3. Nine (60%) patients had a PSA decline of 
50% or more during RLT. Response by baseline to follow-
up change in AP level or 68Ga-PSMA uptake are given in 
Supplemental Table 1.
Table 2: Radiation dose after 30 cycles of 177Lu-PSMA-617 RLT in 15 patients.
Organ (n = 30) Mean (Gy/GBq) SD
Dose limiting organs
Kidney left 0.5 0.3
Kidney right 0.6 0.2




Bone marrow 0.002 0.005
Tumor‡ 6.1 4.9
*determined in ten patients with 2x6.0 GBq 177Lu-PSMA-617 RLT, n = 20; ‡up to three lesions with highest tracer uptake per 
patient and cycle (n = 5 visceral metastases, n = 12 LN metastases, n = 22 bone metastases).
Table 3: Adverse events after 30 cycles of 177Lu-PSMA-617 RLT in 15 patients.
Adverse event Latent Sub-acute
All grades Grade 3 All grades Grade 3
Renal
Glomerular filtration rate (GFR) 8 (53%) 0 1 (7%) 0
Tubular extraction rate (TER) 2 (13%) 0 - -
Hyperkalemia 4 (27%) 0 0 0
Hematologic
Anemia 3 (20%) 0 9 (60%) 1 (7%)
Thrombocytopenia 2 (13%) 0 1 (7%) 0
Leukocytes 7 (47%) 1 (7%) 1 (7%) 0
Liver
Bilirubin 0 0 1 (7%) 0
AST/ALT 2 (13%) 0 1 (7%) 0
Other
Fatigue 5 (33%) 0 0 0
Dry mouth 7 (47%) 0 0 0
Nausea 5 (33%) 1 (7%) 0 0
Dysgeusia 3 (20%) 0 0 0
Absolute number of adverse events (%) are given.
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DISCUSSION
Dosimetry, safety and efficacy of 177Lu-PSMA-617 
RLT were analyzed in 15 patients after a total of 30 
applications. Treatment response was determined by 
RECIST1.1 and a range of secondary endpoints, including 
change in PSA and patient reported outcomes (pain, 
quality of life). In general, we find that 177Lu-PSMA-617 
RLT was tolerated well for both activity regimens, i.e. 
3.7 or 6.0 GBq per cycle. Dose limits for critical organs 
(kidney, 23 Gy [7]; salivary glands, 26-50 Gy [8-9]) were 
not exceeded in any patient. Eight to ten weeks after the 
second application, tumor extent on CT had stabilized or 
showed significant reduction in 10 patients corresponding 
to a disease control rate of 67%. Approximately half of 
patients experienced pain relief and improvement in QoL 
after RLT.
Endoradiotherapy using chelator-bound ligands 
present several advantages over conventional therapy 
for metastatic prostate cancer. Whereas the 68Ga-labelled 
compound provides pre-therapeutic staging and target 
expression levels to PET, the corresponding 177Lu-
labelled compound enables tumor irradiation through 
focal beta emission, while also enabling imaging and 
dosimetry through partial gamma emission. High efficacy 
and safety of 177Lu-based RLT was recently proven in a 
phase III study of patients with advanced-stage mid-gut 
neuroendocrine tumors (NET). In that study, somatostatin 
analogue combination therapy with octreotide plus 
177Lu-DOTATATE versus octreotide alone demonstrated 
approximately 80% risk reduction for NET progression, 
with few serious adverse events [10]. Chelating ligands 
with high affinity to PSMA have been developed for 
imaging (68Ga-HBED-PSMA) and RLT (177Lu-PSMA-617) 
Figure 2: Response after two cycles of 6.0 GBq 177Lu-PSMA-617 RLT. Axial 68Ga-PSMA PET B., D., F., H. and CT A., C., E., 
G. images of the base of the skull and the pelvis before (A, B, C, D) and after (E, F, G, H) two RLT cycles. Brain metastasis (A, B, E, F, 
arrow) and local recurrence (C, D, G, H, double arrow) demonstrate a >30% baseline to follow-up decrease in largest diameter and SUVmax. 
Inguinal lymph node metastasis (C, D, G, arrow) shows complete response on follow-up PET/CT.
Table 4: Response after two cycles 177Lu-PSMA-617 RLT.
n=15 Objective response Patient reported outcomes
RECIST* PSA Pain QoL
After one cycle
CR - 0 1 (7%) -
PR - 7 (47%)** 6 (40%) -
SD - 5 (33%) 2 (13%) -
PD - 3 (20%) 1 (7%) -
After two cycles
CR 0 0 3 (20%) 0
PR 4 (27%) 7 (47%)** 4 (27%) 3 (20%)
SD 6 (40%) 5 (33%) 0 11 (73%)
PD 5 (33%) 3 (20%) 3 (20%) 1 (7%)
*primary outcome, **≥30% decline in PSA; Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors; PSA, 
Prostate-Specific Antigen; QoL, quality of life; SD, stable disease; PR, partial response; PD, progressive disease; CR, complete 
response.
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Figure 3: Best response after 30 cycles of 177Lu-PSMA-617 RLT in 15 patients. Individual response by lowest PSA A., lowest 
pain B. and quality of life (QoL) level C. from start until follow-up after the second RLT cycle is shown. Individual results were arranged by 
best PSA response and separated by regimen (white bars: 2x3.7 GBq; black bars: 2x6.0 GBq). Patient number is given in (A). Bars indicate 
baseline to follow-up change in percent. *no baseline pain noted.
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in order to translate this concept into prostate cancer 
patients [5, 11]. We proved favourable dose distribution, 
and determined safe initial activity for 177Lu-PSMA-617 
RLT (i.e. 6.0 GBq) in an earlier dosimetry trial [6]. This 
cohort was now expanded by ten patients completing 20 
cycles of 6.0 GBq RLT so as to analyze better the clinical 
safety and efficacy of this regimen. In this expanded 
cohort, mean tumor-to-kidney dose ratio was higher 
than the ratio reported for 177Lu-DOTATATE, which is 
the clinical standard for RLT in NET patients [12]. More 
accurate dosimetry using quantitative SPECT reveals an 
approximately 20 to 30% lower radiation dose to salivary 
glands than previously estimated by planar scintigraphy 
[6, 13-14]. Accordingly, the critical dose limits bringing 
loss of salivary function were not exceeded in any patient. 
Indeed, serious adverse events for kidney or salivary 
gland function were not recorded, indicating an excellent 
safety profile of 177Lu-PSMA-617 RLT. Consistent with 
dosimetry and previous clinical findings [14-17] the rate of 
hematologic adverse events was low and few hematologic 
conditions were transient and not life threatening.
Several trials have earlier shown effective reduction 
in tumor burden and serum PSA levels after administration 
of 177Lu-PSMA-617 [14-20]. About one third to half of our 
fifteen patients showed significant improvement after two 
cycles based on CT size and PSA level. Most remarkably, 
one patient with left temporal brain metastasis refractory to 
external beam radiotherapy demonstrated partial response 
after RLT (Figure 2). PSA decline of 50% and more during 
RLT was recorded in nine patients, corresponding to a best 
PSA response rate of 60%. This rate is consistent with 
prior reports from Ahmadzadehfar et al [15], Kratochwil 
et al [14] and with findings for other radio-labelled PSMA 
ligands [21-22]. Rahbar et al and Heck et al demonstrate 
similar rates for PSA decline after one and two RLT cycles 
respectively [16, 23]. When compared to findings from a 
recent study on mCRPC patients, the best PSA response 
was roughly similar to that for Abiraterone treatment and 
higher than for Enzalutamide treatment [24]. Notably, 
all patients with RECIST partial response and 85% of 
patients with ≥30% final PSA decline underwent the 6.0 
GBq RLT regimen. However, single biomarker tests for 
treatment response are unreliable in end-stage prostate 
cancer patients [25]. Accuracy of CT response is limited 
by tumor dissemination and the frequent presence of non-
target bone lesions. Change in PSA or AP levels show 
only modest correlation with clinical benefit [26]. We thus 
chose to systematically record patient-reported outcomes 
using established instruments (Brief Pain Inventory, 
FACT-P) in order to understand better the clinical response 
to RLT. Patient reported outcome was favourable in those 
of our patients with decreasing PSA level during 177Lu-
PSMA-617 RLT: Seven (47%) patients experienced 
significant pain relief and 8 (53%) reported increased QoL 
score after the second cycle.
By including broad range of objective and patient-
reported biomarker endpoints, our study provides a 
detailed analysis of the efficacy of 177Lu-PSMA-617 
RLT. Safety was thoroughly documented by dosimetry 
and frequent follow-up visits for all patients. The present 
study however has limitations. Although patient inclusion 
criteria and treatment protocols were based upon pre-
defined institutional standards, our retrospective data 
analysis may have increased the risk for underreporting 
of adverse events. Furthermore, our inclusion criteria 
resulted in a small patient cohort, which was nonetheless 
representative of mCRPC patients seen at our clinic. 
Furthermore 10 to 20% error for radiation dose calculation 
might be caused by omitting late SPECT acquisition as 
previously estimated for planar scintigraphy [27]. Overall 
results are promising however must be confirmed in a 
randomized trial with longer follow-up period in order to 
monitor for radiation induced, delayed events.
In summary, two cycles of 177Lu-PSMA-617 RLT 
were safe and resulted in promising response rates for 
objective and patient-reported outcomes in fifteen patients 
with metastatic castration-resistant prostate cancer. Based 
on dosimetry more than three cycles of 6.0 GBq RLT 
can be performed with acceptable safety margin. Our 
preliminary data encourage future investigations of 177Lu-




Between September 2014 and May 2016 thirty 
cycles of 177Lu-PSMA-617 RLT were applied in 15 
consecutive patients. The initial five patients received 2 
x 3.7 GBq (n = 10 cycles). Those patients had also been 
included in our previous report on 177Lu-PSMA-617 
dosimetry [6]. The following five patients received a 
higher dose (2 x 6.0 GBq, n = 20 cycles) based on our 
previous recommendation [6]. RLT was offered in 
accordance with the current Declaration of Helsinki, 
paragraph 37 “Unproven Interventions in Clinical 
Practice” and in accordance with German compassionate 
use regulations. Indication was confirmed by both a 
nuclear medicine physician and a urologist or oncologist. 
Patients meeting the following criteria, consistent with 
the German Society of Nuclear Medicine consensus 
panel recommendation [28], were considered for RLT: (a) 
prostate cancer proven by histopathology, (b) unresectable 
metastases, (c) castration resistant disease, (d) completed 
on-label treatment options for castration-resistant 
disease or unfit for such treatments, (e) objective disease 
progression by PSA level and imaging, (f) PSMA-avid 
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lesions on pre-therapeutic 68Ga-HBED-PSMA positron 
emission tomography/computed tomography (PET/CT), 
(g) white blood cell count (WBC) >3000/μl and platelet 
count >75000/μl, (h) creatinine <2-fold the upper limit of 
normal (ULN), (i) AST and ALT <5-fold ULN, and (j) no 
myelosuppressive therapy within six weeks prior to RLT. 
All patients gave written informed consent to undergo 
RLT with subsequent follow-up. Analyses presented in 
this study were performed retrospectively on anonymized 
patient data. The study protocol was approved by the 
local ethics committee and all subjects had provided prior 
written informed consent.
177Lu-PSMA-617 RLT
DOTA-PSMA-617 precursor was obtained from 
ABX GmbH (Radeberg, Germany). In brief, DOTA-
PSMA-617 was dissolved in 1.5 ml of acetate buffer (pH 
4.8) containing 10 mg/ml dihydroxybenzoic acid. The 
solution was added to no-carrier-added 177LuCl3 in 0.04M 
HCl obtained from ITG GmbH (Garching, Germany), 
and heated for 30 min at 90 to 100°C. The amount of 
precursor was 20 µg/GBq 177Lu. Radiochemical yield of 
177Lu-PSMA-617 was greater than 95% and radiochemical 
purities greater than 99% were achieved in each final 
PBS-buffered preparation. Each treatment was performed 
during a four days stay at the Nuclear Medicine ward. 
177Lu-PSMA-617 was given by slow i.v. application over 
twenty minutes. Patients received 50 mg prednisolone and 
1L of 0.9% NaCl i.v. or equivalent amounts of p.o. fluids 
daily until discharge. In order to reduce blood flow and 
radioligand uptake in parotid and submandibular glands, 
ice packs were applied locally from ten min prior to 177Lu-
PSMA-617 administration, and continued for six hours 
thereafter.
Safety and dosimetry
A flow diagram for treatment and follow-up is given 
in Supplemental Figure S1. All patients were monitored 
daily as in-patients for sub-acute toxicity, with physical 
examination and routine bloodwork for electrolytes, 
hematology, liver and kidney function. All patients had 
two follow-up examinations at four to five and eight to ten 
weeks after each RLT cycle, including routine bloodwork 
and one 99mTc-MAG3 renal scintigraphy to monitor latent 
toxicity. The observation period ended on January 31st 
2016. Adverse events for total WBC were graded by 
CTCAE 3.0 [29]. Adverse events for tubular extraction 
rate (TER) were defined as follows: grade 1, 67-100% 
lower limit of normal (LLN); grade 2, 33-66% LLN; grade 
3, 0-32% LLN. The National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0 was used for all other toxicity [30].
Whole body and organ dosimetry was obtained at 
each cycle (n = 30) as described previously [6]. Additional 
quantitative SPECT/CT of the head was performed 
approximately 24, 48 and 72h after each application of 6.0 
GBq 177Lu-PSMA-617 in 10 patients (n = 20) to accurately 
calculate radiation dose to salivary glands, the organ with 
highest absorbed radiation dose in our initial study [6].
Response to RLT and statistical analysis
68Ga-HBED-PSMA PET/CT had been performed 
one to two weeks before the first RTL cycle, and again 
at eight to ten weeks following the second RLT cycle, as 
reported previously [31]. Primary endpoint for efficacy 
was response as determined by RECIST 1.1. Secondary 
endpoints were change in PSA level, pain intensity score, 
and QoL score. PSA and, in case of bone metastases, 
AP blood levels were measured at baseline and each 
subsequent visit. Progressive disease (PD) was defined as 
30% or more increase, partial response (PR) as 30% or 
more decrease in final PSA/AP levels relative to baseline. 
Symptomatic patients reported all four pain severity items 
of the Brief Pain Inventory (BPI) [32] at baseline and 
again at eight to ten weeks after each cycle. In addition, 
any change in pain medication was documented. Here, PD 
was defined as a 30% or greater increase in pain score 
or increase in pain medication, whereas PR was defined 
as corresponding 30% or greater decrease or decrease in 
pain medication. CR was defined as pain score 0 on final 
follow-up. Patients reported QoL based on Functional 
Assessment of Cancer Therapy - Prostate questionnaire 
(FACT-P) [33] at baseline and at eight to ten weeks after 
the second cycle, with PD and PR defined as changes 
of at least 30% relative to baseline QoL score. Stable 
disease (SD) was each defined as non-PD/PR. Results 
are presented as total number (percent), mean ± standard 
deviation (SD), or median (range). Change in baseline to 
follow-up SUVmax was determined as exploratory data for 
up to three lesions with highest SUVmax on baseline 
68Ga-
HBED-PSMA PET. Details for AP and PET response are 
given in the Supplemental Material.
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